Myogene Therapeutics B.V. is a start-up in the cardiology field, based on the pioneering work of Prof. Dr. Jeroen Bakkers and his team at the Hubrecht Institute, Utrecht, NL. Their research in zebrafish has identified a gene and downstream signaling pathway that when activated unlocks the dormant regeneration capacity of the mammalian heart after myocardial infarction (MI).
The recovery process post-MI presents significant challenges, including the heart’s limited ability to regenerate damaged tissues, leading to irreversible loss of cardiac function. Our envisioned therapy employs cutting-edge genetic engineering techniques to stimulate heart regeneration.
By targeting a specific gene and its downstream signalling pathway we can promote the restoration of damaged heart muscle, recover heart function and improve patient outcomes post-MI.
The global market for post-MI treatments is vast and growing, driven by an aging population and increasing rates of cardiovascular diseases. Current treatments focus on managing symptoms and preventing further damage, leaving a significant gap for therapies that can actively regenerate heart tissue and cure the disease.
Myogene is positioned to capture a substantial portion of this market, offering a novel solution that goes beyond symptom management to address the root cause of post-MI complications. Myogene represents a groundbreaking advancement in the treatment of MI. With its innovative approach to cardiac regeneration, strong market potential, and competitive advantages, we are poised to lead a new era in cardiovascular therapy.
We invite you to be part of this life-saving journey.